(Q36832137)

16 August 2017

1 reference

title

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies (English)

1 reference

16 August 2017

Leonard JP

1

1 reference

16 August 2017

Goldenberg DM

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

25

1 reference

16 August 2017

page(s)

3704-3713

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210370

16 August 2017

exact match

0 references

cites work

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Role of GITR in activation response of T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Radioimmunotherapy of non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

State-of-the-art therapeutics: diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

The radioisotope contributes significantly to the activity of radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Prolonging remission with rituximab maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Treatment strategies in follicular lymphomas: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

The pathogenesis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

The role of CD22 and other inhibitory co-receptors in B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

CD22 is a negative regulator of B-cell receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Hyperresponsive B cells in CD22-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

CD22 regulates thymus-independent responses and the lifespan of B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Cyclooxygenase-2 inhibitors in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Cell cycle oscillation of phosphatase inhibitor-2 in rat fibroblasts coincident with p34cdc2 restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Lymphoma: diagnosis, staging, natural history, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

Therapy of non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Diffuse aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Mantle cell lymphoma: current concept in biology and treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Clinical utility of radioimmunoscintigraphy of non-Hodgkin's lymphoma with radiolabelled LL2 monoclonal antibody, LymphoSCAN: preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Advancing role of radiolabeled antibodies in the therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Lymphoma imaging with a new technetium-99m labelled antibody, LL2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Non-Hodgkin's lymphomas: current classification and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

1 reference

7 January 2021

Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210370

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210370

1 reference

release_o5j7i5r63rdcdjfc7xtzl3smdu

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o5j7i5r63rdcdjfc7xtzl3smdu

24 November 2022

mapped directly with Wikidata item

1 reference